Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. ACN
5. IBM
6. META
7. SPY
8. NVDA
9. PRIM
10. PFE

Go back to Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

Edwards Lifesciences (EW) shares rally on Evoque FDA approval

February 2, 2024 11:26 AM EST

Edwards Lifesciences (NYSE: EW) shares are rallying Friday after the companys EVOQUE tricuspid valve replacement system was approved by the U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

EW shares are up more than 7% at $84.50 per share at the... More